C10
Arzneimittelforschung
1992 Jul;42(7):964-8
Pharmacokinetics
of silybin in bile following administration of silipide (Siliphos®)
and silymarin in cholecystectomy patients.
Schandalik
R, Gatti G, Perucca E
Surgical
Department, Regional Hospital, Braunau am Inn, Austria.
These
data indicate that the bioavailability of silybin is much
greater after administration of silipide (Siliphos®) than
after administration of silymarin. This results in increased
delivery of the compound to the liver, which represents the
target organ for pharmacological action.
The biliary
excretion of silybin, the main active component of silymarin,
was evaluated by using a specific HPLC method in 9 cholecystectomy
patients with T-tube drainage after intake of oral doses of
silipide (Siliphos®) (Siliphos®) and of silymarin
(120mg expressed as silybin equivalents)
After
intake of silipide (Siliphos®), the concentration of silybin
in bile reached a peak within 4 h and declined thereafter
with a mean time of about 10 h. After administration of silymarin,
biliary silybin concentrations were several-fold lower than
those observed after intake of silipide (Siliphos®).
The bile
collected after silymarin intake also contained considerable
amounts of isosilybin (a silybin isomer) and very low levels
of silydianin and silycristin. The amount of silybin recovered
in bile in free and conjugated form within 48 h accounted
for 11% of the dose after silipide (Siliphos®) and for
3% of the dose after silymarin. Plasma silybin concentrations,
determined in 3 subjects, were several-fold lower than those
in bile after intake of silipide (Siliphos®) and mostly
undetectable after intake of silymarin.
C10
|
